Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2019-02-13 | 2020-08-10 | 75632 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2017-05-24 | 2017-07-19 | 11053 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2017-08-08 | 2017-09-22 | 18567 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-07 | 2023-12-22 | 203843 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-15 | 2023-12-22 | 204417 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-12-01 | 2024-01-05 | 212377 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2018-11-16 | 2019-01-17 | 67034 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-04-08 | 2022-06-12 | 158373 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-07-22 | 2022-09-01 | 165335 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-10-21 | 2023-01-06 | 172347 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-05-26 | 2023-06-16 | 193212 |
| APO-TERIFLUNOMIDE | 14MG | TABLET | Resolved | 2023-10-27 | 2024-01-12 | 208385 |
| APO-TERIPARATIDE INJECTION | 250MCG | SOLUTION | Resolved | 2025-03-20 | 2025-05-02 | 253081 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2024-01-05 | 2024-02-02 | 215212 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2021-08-16 | 2021-09-07 | 144209 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2021-04-05 | 2021-05-03 | 136814 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2020-06-24 | 2020-10-13 | 118781 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2017-09-07 | 2017-11-22 | 21209 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2018-01-31 | 2018-05-16 | 37749 |
| APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2023-08-23 | 2023-10-06 | 202818 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |